Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Exclusion Criteria

• •Patients will not be eligible for this study if they:
• •Have taken nonnucleoside reverse transcriptase inhibitors.
• •Have taken other anti-HIV drugs for 2 weeks or more.
• •Have an opportunistic (AIDS-related) infection.
• •Are pregnant or breast-feeding.
• •Have had hepatitis within the past 6 months.
• •Are allergic to the study drugs or their ingredients.
• •Have a mental, physical, or substance abuse disorder.
• •Have a serious medical condition, such as diabetes, congestive heart failure, or other heart disease.
• •Have a gastrointestinal disorder that affects drug absorption or makes it difficult to take medication by mouth.
• •Have received within 4 weeks before study entry, or may require during the study period, radiation therapy, chemotherapy, or drugs that affect the immune system (such as steroid drugs, interleukins, vaccines, or interferons).
• •Have received an HIV vaccine within 3 months before study entry, or are scheduled to receive one during the study period.
• •Require foscarnet or other drugs that are shown to be effective against HIV.
• •Are taking astemizole, cisapride, midazolam, triazolam, or ergot derivatives.
• •Are taking experimental drugs.
• •Are unlikely to complete the study or take the drugs.